Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan
Viveve Medical, Inc. (NASDAQ:VIVE) announced the issuance of Taiwan Patent No. I766557 for its dual-energy technology, enhancing its intellectual property in a significant Asian market. CEO Scott Durbin emphasized the importance of this patent for Viveve's global clinical development and commercialization strategies, particularly for treating stress urinary incontinence (SUI) in women. The Viveve System is already approved for various surgical procedures in Taiwan, with distribution managed by Dynamic Medical Technologies.
- Issuance of Taiwan Patent No. I766557 strengthens Viveve's IP position.
- Potential expansion in the Asian market for Viveve's technology.
- Viveve's technology is already cleared for use in surgical procedures in Taiwan.
- None.
ENGLEWOOD, CO / ACCESSWIRE / July 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve's dual-energy technology. The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.
"This most recent patent decision represents an important advance in our IP position because Taiwan is a key international market for our technology and plays an important role in influencing women's medical and health trends throughout Asia," said Scott Durbin, Viveve's chief executive officer. "With our robust and growing intellectual property estate, we continue to advance our global clinical development and commercialization strategy toward a potential new indication in the U.S. for the treatment of stress urinary incontinence in women."
In Taiwan, the Viveve® System is indicated for use in general surgical procedures for anticoagulation and hemostasis. Dynamic Medical Technologies, Inc. remains Viveve's exclusive distribution partner in the country.
About Viveve
Viveve Medical, Inc. is a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI). Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in 50 countries.
Viveve continues to advance its clinical development program in SUI. Viveve received FDA approval of its Investigational Device Exemption (IDE) application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT trial for improvement of SUI in women in July 2020 and FDA approval of its requested amendments to the IDE protocol in December 2020. Initiation of the trial was reported in January 2021 and completion of subject enrollment was announced on December 14, 2021. Topline results are anticipated at the end of 2022. If positive, results from the PURSUIT trial may support a new SUI indication in the U.S.
For more information visit www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Viveve Medical, Inc.'s plans, timelines, or presumptions of results for the PURSUIT trial, and the expected impact of the issuance of Taiwan Patent No. I766557 on Viveve Medical, Inc.'s ability to market its technology in Taiwan and Asia. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our clinical trials, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.
Viveve is a registered trademark of Viveve, Inc.
Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
Media Contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com
SOURCE: Viveve Medical, Inc.
View source version on accesswire.com:
https://www.accesswire.com/708188/Viveve-Announces-Expansion-of-IP-Portfolio-with-Patent-Issuance-in-Taiwan
FAQ
What is the significance of Taiwan Patent No. I766557 for Viveve Medical?
What technology does Viveve Medical focus on?
How does the new patent affect Viveve's commercialization strategy?
Who is Viveve's distribution partner in Taiwan?
What procedures is the Viveve System approved for in Taiwan?
